[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,215
  • Shares Outstanding, K 34,647
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,850 K
  • EBIT $ -41 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.24

Options Overview Details

View History
  • Implied Volatility 533.70% (+370.28%)
  • Historical Volatility 123.48%
  • IV Percentile 77%
  • IV Rank 45.04%
  • IV High 1,160.30% on 08/04/25
  • IV Low 20.18% on 01/06/26
  • Expected Move (DTE 2) 0.1870 (9.64%)
  • Put/Call Vol Ratio 2.13
  • Today's Volume 200
  • Volume Avg (30-Day) 1,554
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 25,818
  • Open Int (30-Day) 25,023
  • Expected Range 1.7530 to 2.1270

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7300 +6.36%
on 04/24/26
2.4705 -25.52%
on 05/11/26
-0.0800 (-4.17%)
since 04/20/26
3-Month
1.5407 +19.43%
on 04/10/26
3.0288 -39.25%
on 03/17/26
-0.6400 (-25.81%)
since 02/20/26
52-Week
1.5407 +19.43%
on 04/10/26
5.5000 -66.55%
on 11/28/25
-0.3000 (-14.02%)
since 05/20/25

Most Recent Stories

More News
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 New...

ANVS : 1.8200 (-6.19%)
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated,...

ANVS : 1.8200 (-6.19%)
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Financing secures path to first NDA submission for buntanetap 6-Month symptomatic data readout anticipated Q1 2027 Alzheimer’s disease Phase 3 trial 75% enrolled Parkinson's disease open-label...

ANVS : 1.8200 (-6.19%)
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)
Annovis Publishes Historical Review of Buntanetap in The Scientist

MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.8200 (-6.19%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 2.1267
2nd Resistance Point 2.0833
1st Resistance Point 2.0117
Last Price 1.8200
1st Support Level 1.8967
2nd Support Level 1.8533
3rd Support Level 1.7817

See More

52-Week High 5.5000
Fibonacci 61.8% 3.9875
Fibonacci 50% 3.5203
Fibonacci 38.2% 3.0532
Last Price 1.8200
52-Week Low 1.5407

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.